Pdt Partners, LLC Protagonist Therapeutics, Inc Transaction History

Pdt Partners, LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$7.36 - $11.17 $325,334 - $493,747	-44,203 Reduced 35.07%	81,835 $892,000
Q3 2022 Nov 14, 2022	BUY	$7.86 - $11.71 $294,435 - $438,656	37,460 Added 42.29%	126,038 $1.06 Million
Q2 2022 Aug 15, 2022	BUY	$7.06 - $25.52 $512,626 - $1.85 Million	72,610 Added 454.72%	88,578 $701,000
Q1 2022 May 16, 2022	SELL	$23.34 - $36.08 $1,167 - $1,804	-50 Reduced 0.31%	15,968 $378,000
Q4 2021 Feb 14, 2022	SELL	$17.63 - $37.1 $241,213 - $507,602	-13,682 Reduced 46.07%	16,018 $548,000
Q3 2021 Nov 15, 2021	BUY	$12.95 - $49.69 $384,615 - $1.48 Million	29,700 New	29,700 $526,000
Q2 2020 Aug 14, 2020	SELL	$6.19 - $18.84 $194,495 - $591,971	-31,421 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$5.4 - $9.22 $64,719 - $110,501	-11,985 Reduced 27.61%	31,421 $222,000
Q4 2019 Feb 14, 2020	BUY	$4.69 - $13.45 $111,551 - $319,908	23,785 Added 121.22%	43,406 $306,000
Q3 2019 Nov 14, 2019	BUY	$9.41 - $16.56 $43,380 - $76,341	4,610 Added 30.71%	19,621 $236,000
Q2 2019 Aug 14, 2019	BUY	$8.98 - $12.96 $134,798 - $194,542	15,011 New	15,011 $182,000
Q1 2018 May 15, 2018	SELL	$8.46 - $23.08 $256,050 - $698,539	-30,266 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$14.47 - $20.8 $63,176 - $90,812	4,366 Added 16.86%	30,266 $630,000
Q3 2017 Nov 14, 2017	BUY	$10.61 - $17.98 $274,799 - $465,682	25,900	25,900 $458,000

247

56.4M

76.3K

114K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $1.92B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.